|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002475,
umls-concept:C0008838,
umls-concept:C0013089,
umls-concept:C0013216,
umls-concept:C0015385,
umls-concept:C0018183,
umls-concept:C0020823,
umls-concept:C0087111,
umls-concept:C0205225,
umls-concept:C0205265,
umls-concept:C0543467,
umls-concept:C1261473,
umls-concept:C1521761,
umls-concept:C1522449,
umls-concept:C1555582
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-2-21
|
|
pubmed:abstractText |
Most institutional teams utilize multimodality therapy in their efforts to cure patients with primary high-grade extremity soft tissue sarcomas, although the value of adjuvant systemic chemotherapy is still disputed by some oncologists. This single-institution Phase II study describes an effort to control metastasis by the use of two cycles of chemotherapy as the initial preoperative treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:BucknerJan CJC,
pubmed-author:EdmonsonJohn HJH,
pubmed-author:FooMay LML,
pubmed-author:GundersonLeonard LLL,
pubmed-author:HaddockMichael GMG,
pubmed-author:MahoneyMichelle RMR,
pubmed-author:MaplesWilliam JWJ,
pubmed-author:O'ConnorMary IMI,
pubmed-author:PetersenIvy AIA,
pubmed-author:PritchardDouglas JDJ,
pubmed-author:RockMichael GMG,
pubmed-author:ShivesThomas CTC,
pubmed-author:SimFranklin HFH,
pubmed-author:StaffordScott LSL
|
|
pubmed:copyrightInfo |
Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10259
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
786-92
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:11857314-Adult,
pubmed-meshheading:11857314-Aged,
pubmed-meshheading:11857314-Aged, 80 and over,
pubmed-meshheading:11857314-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11857314-Cisplatin,
pubmed-meshheading:11857314-Combined Modality Therapy,
pubmed-meshheading:11857314-Doxorubicin,
pubmed-meshheading:11857314-Female,
pubmed-meshheading:11857314-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:11857314-Humans,
pubmed-meshheading:11857314-Ifosfamide,
pubmed-meshheading:11857314-Infusions, Intravenous,
pubmed-meshheading:11857314-Injections, Subcutaneous,
pubmed-meshheading:11857314-Leukopenia,
pubmed-meshheading:11857314-Male,
pubmed-meshheading:11857314-Mesna,
pubmed-meshheading:11857314-Middle Aged,
pubmed-meshheading:11857314-Mitomycin,
pubmed-meshheading:11857314-Neoadjuvant Therapy,
pubmed-meshheading:11857314-Sarcoma,
pubmed-meshheading:11857314-Soft Tissue Neoplasms,
pubmed-meshheading:11857314-Thrombocytopenia,
pubmed-meshheading:11857314-Treatment Outcome,
pubmed-meshheading:11857314-Vomiting
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
|
|
pubmed:affiliation |
Mayo Clinic, Rochester, Minnesota 55905, USA. edmoj@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
